U.S. Biotech Stock News

DoorDash (DASH) has quietly outperformed the broader market this year, with the stock up roughly 36% year to date and about 35% over the past year, drawing fresh attention to its valuation. See our latest analysis for DoorDash. That strength has not been a straight line, with a 23.38% 1 month share price return contrasting with a weaker 90 day patch, but the longer term trend and three year total shareholder return of 395.33% still point to solid momentum. If DoorDash has you rethinking...

KULR Technology Group (KULR) just hit pause on its stock issuance while doubling down on a new battery backup partnership for AI scale data centers. This move tightly links liquidity, focus, and future demand. See our latest analysis for KULR Technology Group. The latest BBU collaboration and ATM pause land after a sharp swing in sentiment, with a 48.13 percent 1 month share price return to 3.57 following an 85.32 percent year to date share price decline and deeply negative multi year total...

Wondering if MSC Industrial Direct is still good value after its recent run, or if the easy money has already been made? Let us break down what the current price might really be telling you about future returns. The stock has inched up about 1.1% over the last week and is flat over 30 days, but it is still up around 15.7% year to date and 18.3% over the past year, suggesting steady optimism rather than a speculative spike. That gradual climb has come as investors focus on MSC Industrial...

Equifax (EFX) just delivered a third quarter that beat its own revenue guidance while navigating a choppy mortgage and hiring backdrop, and the upside is increasingly tied to its AI and cloud playbook. See our latest analysis for Equifax. Even with today’s Q3 beat and a steady stream of AI and cloud patent wins, the stock’s 1 month share price return of 5.22 percent comes against a softer year to date share price return and a modestly positive 3 year total shareholder return. This suggests...

Wondering if Eaton at around $323 a share is still a smart buy or if most of the upside is already priced in? Let us unpack what the market might be missing in the current valuation. Even after a modest 2.5% gain over the last week, the stock is still down 2.0% over the past month and 2.5% year to date. This looks like a pause after a powerful multi year run of 116.9% over three years and 195.2% over five. Recent headlines have focused on Eaton as a key beneficiary of long term spending on...

Wondering if Deluxe is quietly trading below what it is really worth? Let us walk through the numbers to see whether the recent price still offers value or if most of the upside has already been priced in. Over the last month the stock has climbed 12.7%, building on a 5.4% gain over the past year and a strong 63.3% return over three years, even though it is slightly down 0.7% year to date and off 3.0% this week. Those moves come as investors refocus on Deluxe as a diversified payments and...

If you are wondering whether Williams-Sonoma is still a bargain after its huge run up, you are not alone. This stock has quietly turned into one of the market's standout retail winners. The share price is now around $189.47, up roughly 2.0% over the past week, 9.1% over the last month, and an eye catching 249.2% over three years. This naturally raises the question of how much upside is really left. Investors have been reacting to a steady drumbeat of positive business updates, from strong...

Westlake Corporation has approved and begun implementing a plan to cease operations at several North American chlorovinyl and styrene production facilities by December 2025, incurring about US$415 million in pre-tax closure-related costs and reducing its workforce by roughly 295 employees. The company will discuss these closures on a special call as part of a broader effort to improve profitability in its Performance & Essential Materials segment while consolidating production across its...

IDEAYA Biosciences (IDYA) just hit a key milestone, completing enrollment in its Phase 2/3 OptimUM-02 trial for darovasertib in first line metastatic uveal melanoma, a step that may reshape expectations around future approvals. See our latest analysis for IDEAYA Biosciences. The milestone has arrived against a strong backdrop, with IDEAYA’s 90 day share price return of 38.89 percent and three year total shareholder return of 104.24 percent signaling momentum that investors increasingly see as...

PagSeguro Digital (NYSE:PAGS) has quietly turned into a recovery story, with the stock up more than 50% this year even after a choppy past month. That move has investors revisiting its long term potential. See our latest analysis for PagSeguro Digital. At around $9.75, the recent pullback sits against a powerful year to date share price return of just over 50 percent. A 1 year total shareholder return near 60 percent signals that sentiment has been steadily rebuilding rather than fading. If...

In October 2025, law firm Levi & Korsinsky began investigating Lennox International for potential federal securities law violations after the company reported mixed third-quarter results, revenue declines, inventory challenges, and revised full-year guidance. This combination of operational setbacks and legal scrutiny raises fresh questions about Lennox’s risk controls, demand visibility, and the resilience of its longer-term business plan. Against this backdrop of an investigation tied to...

Earlier this week, analysts reiterated a positive stance on Cheniere Energy Partners, emphasizing its Sabine Pass LNG operations and long-term, fee-based contracts that cover most of its production and underpin relatively predictable cash flows. An important nuance for income-focused investors is that this contract structure, combined with the proposed Sabine Pass Expansion Project, is seen as supporting the partnership’s ability to maintain and potentially grow cash distributions over...

Earlier this week, Madison Square Garden Sports, Madison Square Garden Entertainment, and Sphere Entertainment announced a multi-year marketing partnership naming PwC US the Official Business Consulting Partner of Madison Square Garden’s arena, the New York Knicks, and the New York Rangers, with expanded visibility across venues and digital platforms. An important element of the agreement is PwC’s role, beginning in 2026, as presenting partner of the Knicks’ “Season of Giving” community...

Wondering if Ferrari at around $376 a share is a luxury brand on sale or a status symbol priced for perfection? This breakdown is designed to give you a clear, no nonsense view of what you are really paying for. Despite being down about 9.6% year to date and roughly 12.6% over the last year, Ferrari is still sitting on a 3 year gain of about 82.8% and around 69.3% over 5 years. This indicates that long term holders have still done very well even after the recent wobble. Recent moves in the...

Accenture (ACN) has quietly staged a meaningful rebound over the past month, climbing about 11% after a tough year in which the stock is still down roughly 23% year to date. See our latest analysis for Accenture. That recent 30 day share price return of about 11%, taking Accenture to around $269.98, stands in contrast to its negative year to date share price performance and softer one year total shareholder return. This hints that sentiment may be stabilising after a reset. If this rebound...

ITT (ITT) has quietly rewarded patient investors, with the stock up around 25% year to date despite a slight pullback this month. Under the hood, the industrial fundamentals look stronger than the recent price suggests. See our latest analysis for ITT. That climb has not been a straight line. The latest dip followed a strong run where the 7 day share price return was 3.28 percent and the 3 year total shareholder return reached 130.09 percent, suggesting momentum is still broadly constructive...

Netflix (NFLX) has quietly slipped over the past month, down about 12%, even though earnings and revenue are still growing at a healthy clip. That disconnect between fundamentals and share price is what matters here. See our latest analysis for Netflix. Zooming out, Netflix shares are still up on a year to date basis despite a roughly 12% one month share price pullback. That comes after a powerful three year total shareholder return above 200% that now has some investors reassessing how much...

General Electric (GE) is back in focus after a pair of aerospace wins: a major LEAP-1B engine deal with Pegasus Airlines and a fresh U.S. Navy R&D contract on its F414 fighter jet engine program. See our latest analysis for General Electric. Those deals land against a backdrop of powerful momentum, with the share price up strongly over the past year and a multi year total shareholder return above 500 percent, signaling renewed confidence in GE Aerospace’s growth runway. If GE’s surge has you...

Why NVIDIA Stock Is Back in Focus Nvidia (NVDA) shares have quietly climbed about 10% over the past week, outpacing the broader market and putting the spotlight back on what investors are actually paying for its rapid AI led growth. See our latest analysis for NVIDIA. That 10.3% 7 day share price return comes on top of a strong year to date move, with NVIDIA still riding a powerful AI infrastructure cycle even after a multi year total shareholder return in the four digit range. This suggests...

If you have been wondering whether Keurig Dr Pepper is quietly turning into a value opportunity or just a value trap, you are not alone. This is exactly what we are going to unpack. The stock has drifted lower over the longer term, with returns of about -11.1% over the last year and -11.8% year to date, even though it has managed a modest 2.3% gain over the last month. Recently, the company has stayed in the headlines for portfolio reshuffles, new beverage partnerships, and ongoing...

Wondering if Teradyne is still attractive after its big run, or if you would just be paying up for yesterday's gains? This breakdown will help you think through whether the current price really makes sense. Teradyne's share price has climbed to about $198.53, with returns of 7.2% over the last week, 19.6% over the last month, and 56.9% year to date, building on a 53.4% gain over the past year and 138.7% over three years. That surge has come alongside growing interest in semiconductor test...

Nutex Health has opened its 26th hospital and first Missouri location, Archview ER & Hospital in St. Louis, a 16,000-square-foot facility with 15 emergency beds, 3 inpatient suites, and full-service lab and advanced imaging available 24/7/365. This move extends Nutex Health’s micro-hospital footprint into a new state, underlining its focus on smaller, technology-equipped facilities aimed at convenient community care. We’ll now look at how this Missouri micro-hospital opening fits into Nutex...

AiRWA (YYAI) has quietly posted a strong 1 day jump of about 6% and a roughly 18% gain over the past week, even though the longer term chart still looks rough. See our latest analysis for AiRWA. Those sharp 1 day and 7 day share price returns sit against a brutal year to date share price return of about negative 98 percent and a similar one year total shareholder return. As a result, the latest bounce looks more like speculative momentum than a clear turnaround. If AiRWA’s volatility has your...

Celsius Holdings (CELH) has had a strong run lately, with the stock up about 18% over the past month and more than 60% this year, even after a choppy past 3 months. See our latest analysis for Celsius Holdings. That recent pop in Celsius Holdings comes after a more volatile stretch, but the stock still shows strong momentum overall, with a 64.41% year to date share price return and a 63.45% one year total shareholder return. If Celsius’s surge has you rethinking your watchlist, it might be a...